Hepion Historical Financial Ratios

HEPA Stock

USD 0.63 0.04 5.97%

Hepion Pharmaceuticals is recently reporting on over 98 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 1.86 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Hepion Pharmaceuticals financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.

About Hepion Financial Ratios Analysis

Hepion PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Hepion Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Hepion financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Hepion Pharmaceuticals history.

Hepion Pharmaceuticals Financial Ratios Chart

At present, Hepion Pharmaceuticals' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Average Payables is expected to grow to about 2.6 M, whereas Book Value Per Share is forecasted to decline to 1.74.

Average Payables Payables Turnover Cash Per Share Days Payables Outstanding

Add Fundamental

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most ratios from Hepion Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Hepion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.At present, Hepion Pharmaceuticals' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Average Payables is expected to grow to about 2.6 M, whereas Book Value Per Share is forecasted to decline to 1.74.

	2021	2022	2023	2024 (projected)
Net Debt To EBITDA	3.0	1.17	0.3	0.28
Intangibles To Total Assets	0.0489	0.053	0.0609	0.0578

Net Debt To E B I T D A Intangibles To Total Assets

Hepion Pharmaceuticals fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Net Income Per Share	Payables Turnover	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Intangibles To Total Assets	Net Debt To E B I T D A
Ptb Ratio		0.1	-0.39	-0.32	0.6	-0.8	1.0	-0.32	-0.95	-0.34	0.32	0.35	1.0	-0.31	0.67	1.0	-0.2	0.71	-0.53	1.0	1.0	0.96	1.0	-0.42	-0.36	-0.08
Book Value Per Share	0.1		0.0	-0.47	0.14	-0.44	0.1	-0.47	-0.19	-0.2	-0.04	0.33	0.09	0.1	0.37	0.09	0.06	0.39	-0.35	0.09	0.09	0.12	0.09	0.07	0.0	-0.25
Free Cash Flow Yield	-0.39	0.0		-0.14	-0.51	0.5	-0.39	-0.14	0.45	-0.28	-0.31	0.29	-0.39	0.52	-0.42	-0.39	0.45	-0.59	0.46	-0.39	-0.4	-0.25	-0.39	0.92	0.06	0.42
Operating Cash Flow Per Share	-0.32	-0.47	-0.14		0.18	0.23	-0.32	1.0	0.48	0.91	0.41	-0.94	-0.32	-0.39	-0.22	-0.32	-0.66	-0.32	0.63	-0.32	-0.31	-0.23	-0.32	-0.23	-0.4	0.44
Average Payables	0.6	0.14	-0.51	0.18		-0.76	0.6	0.18	-0.59	0.28	0.28	-0.24	0.6	-0.81	0.74	0.6	-0.35	0.45	-0.37	0.6	0.6	0.63	0.6	-0.66	-0.78	0.17
Capex To Depreciation	-0.8	-0.44	0.5	0.23	-0.76		-0.8	0.23	0.84	0.03	-0.39	-0.14	-0.8	0.46	-0.92	-0.8	0.26	-0.77	0.66	-0.8	-0.8	-0.81	-0.8	0.54	0.52	0.13
Pb Ratio	1.0	0.1	-0.39	-0.32	0.6	-0.8		-0.32	-0.95	-0.34	0.32	0.35	1.0	-0.31	0.67	1.0	-0.2	0.71	-0.53	1.0	1.0	0.96	1.0	-0.42	-0.36	-0.08
Free Cash Flow Per Share	-0.32	-0.47	-0.14	1.0	0.18	0.23	-0.32		0.48	0.91	0.41	-0.94	-0.32	-0.39	-0.22	-0.32	-0.65	-0.32	0.63	-0.32	-0.31	-0.23	-0.32	-0.23	-0.4	0.44
Roic	-0.95	-0.19	0.45	0.48	-0.59	0.84	-0.95	0.48		0.43	-0.2	-0.45	-0.95	0.32	-0.76	-0.95	0.03	-0.7	0.76	-0.95	-0.95	-0.87	-0.95	0.49	0.3	0.27
Net Income Per Share	-0.34	-0.2	-0.28	0.91	0.28	0.03	-0.34	0.91	0.43		0.45	-0.93	-0.33	-0.41	-0.03	-0.33	-0.63	-0.09	0.47	-0.33	-0.32	-0.21	-0.33	-0.31	-0.39	0.4
Payables Turnover	0.32	-0.04	-0.31	0.41	0.28	-0.39	0.32	0.41	-0.2	0.45		-0.44	0.32	-0.36	0.19	0.32	-0.76	0.44	0.1	0.32	0.33	0.42	0.32	-0.29	-0.33	0.37
Cash Per Share	0.35	0.33	0.29	-0.94	-0.24	-0.14	0.35	-0.94	-0.45	-0.93	-0.44		0.35	0.42	0.18	0.35	0.62	0.22	-0.47	0.35	0.34	0.27	0.35	0.32	0.34	-0.38
Pocfratio	1.0	0.09	-0.39	-0.32	0.6	-0.8	1.0	-0.32	-0.95	-0.33	0.32	0.35		-0.31	0.67	1.0	-0.2	0.71	-0.52	1.0	1.0	0.96	1.0	-0.43	-0.37	-0.08
Interest Coverage	-0.31	0.1	0.52	-0.39	-0.81	0.46	-0.31	-0.39	0.32	-0.41	-0.36	0.42	-0.31		-0.55	-0.31	0.52	-0.12	0.23	-0.31	-0.31	-0.29	-0.31	0.74	0.76	-0.08
Capex To Operating Cash Flow	0.67	0.37	-0.42	-0.22	0.74	-0.92	0.67	-0.22	-0.76	-0.03	0.19	0.18	0.67	-0.55		0.67	-0.13	0.56	-0.67	0.67	0.68	0.68	0.67	-0.55	-0.61	-0.23
Pfcf Ratio	1.0	0.09	-0.39	-0.32	0.6	-0.8	1.0	-0.32	-0.95	-0.33	0.32	0.35	1.0	-0.31	0.67		-0.2	0.71	-0.52	1.0	1.0	0.96	1.0	-0.43	-0.37	-0.08
Days Payables Outstanding	-0.2	0.06	0.45	-0.66	-0.35	0.26	-0.2	-0.65	0.03	-0.63	-0.76	0.62	-0.2	0.52	-0.13	-0.2		-0.26	-0.32	-0.2	-0.21	-0.24	-0.2	0.46	0.39	-0.19
Income Quality	0.71	0.39	-0.59	-0.32	0.45	-0.77	0.71	-0.32	-0.7	-0.09	0.44	0.22	0.71	-0.12	0.56	0.71	-0.26		-0.48	0.71	0.72	0.71	0.71	-0.41	-0.01	-0.1
Roe	-0.53	-0.35	0.46	0.63	-0.37	0.66	-0.53	0.63	0.76	0.47	0.1	-0.47	-0.52	0.23	-0.67	-0.52	-0.32	-0.48		-0.52	-0.52	-0.38	-0.52	0.48	0.05	0.56
Ev To Operating Cash Flow	1.0	0.09	-0.39	-0.32	0.6	-0.8	1.0	-0.32	-0.95	-0.33	0.32	0.35	1.0	-0.31	0.67	1.0	-0.2	0.71	-0.52		1.0	0.96	1.0	-0.43	-0.37	-0.08
Pe Ratio	1.0	0.09	-0.4	-0.31	0.6	-0.8	1.0	-0.31	-0.95	-0.32	0.33	0.34	1.0	-0.31	0.68	1.0	-0.21	0.72	-0.52	1.0		0.96	1.0	-0.43	-0.37	-0.08
Return On Tangible Assets	0.96	0.12	-0.25	-0.23	0.63	-0.81	0.96	-0.23	-0.87	-0.21	0.42	0.27	0.96	-0.29	0.68	0.96	-0.24	0.71	-0.38	0.96	0.96		0.96	-0.3	-0.48	0.14
Ev To Free Cash Flow	1.0	0.09	-0.39	-0.32	0.6	-0.8	1.0	-0.32	-0.95	-0.33	0.32	0.35	1.0	-0.31	0.67	1.0	-0.2	0.71	-0.52	1.0	1.0	0.96		-0.43	-0.37	-0.08
Earnings Yield	-0.42	0.07	0.92	-0.23	-0.66	0.54	-0.42	-0.23	0.49	-0.31	-0.29	0.32	-0.43	0.74	-0.55	-0.43	0.46	-0.41	0.48	-0.43	-0.43	-0.3	-0.43		0.36	0.39
Intangibles To Total Assets	-0.36	0.0	0.06	-0.4	-0.78	0.52	-0.36	-0.4	0.3	-0.39	-0.33	0.34	-0.37	0.76	-0.61	-0.37	0.39	-0.01	0.05	-0.37	-0.37	-0.48	-0.37	0.36		-0.37
Net Debt To E B I T D A	-0.08	-0.25	0.42	0.44	0.17	0.13	-0.08	0.44	0.27	0.4	0.37	-0.38	-0.08	-0.08	-0.23	-0.08	-0.19	-0.1	0.56	-0.08	-0.08	0.14	-0.08	0.39	-0.37

Click cells to compare fundamentals

Hepion Pharmaceuticals Account Relationship Matchups

High Positive Relationship

Pb Ratio	+ 1.0	Ptb Ratio
Pocfratio	+ 1.0	Ptb Ratio
Pfcf Ratio	+ 1.0	Ptb Ratio
Ev To Operating Cash Flow	+ 1.0	Ptb Ratio
Pe Ratio	+ 1.0	Ptb Ratio
Ev To Free Cash Flow	+ 1.0	Ptb Ratio

High Negative Relationship

Ev To Free Cash Flow	- 0.95	Roic
Pe Ratio	- 0.95	Roic
Ev To Operating Cash Flow	- 0.95	Roic
Pfcf Ratio	- 0.95	Roic
Pocfratio	- 0.95	Roic
Roic	- 0.95	Pb Ratio

Hepion Pharmaceuticals fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	0.7	0.52	0.86	0.46	1.77	1.86
Book Value Per Share	152.86	83.74	26.46	13.08	1.83	1.74
Free Cash Flow Yield	(0.7)	(0.77)	(0.39)	(1.53)	(3.18)	(3.02)
Operating Cash Flow Per Share	(74.05)	(33.41)	(8.88)	(9.17)	(10.3)	(10.81)
Pb Ratio	0.7	0.52	0.86	0.46	1.77	1.86
Free Cash Flow Per Share	(74.55)	(33.59)	(8.92)	(9.18)	(10.3)	(10.82)
Roic	(0.43)	(0.49)	(0.33)	(0.85)	(6.6)	(6.27)
Net Income Per Share	(68.88)	(42.06)	(9.31)	(11.07)	(12.32)	(12.94)
Payables Turnover	0.0544	0.009272	0.0352	0.0291	0.0286	0.0188
Cash Per Share	136.28	84.17	25.99	13.43	3.72	3.54
Pocfratio	(1.45)	(1.31)	(2.57)	(0.65)	(0.31)	(0.33)
Interest Coverage	(14.0)	(645.11)	(3.4K)	(4.5K)	(5.1K)	(4.9K)
Pfcf Ratio	(1.44)	(1.3)	(2.56)	(0.65)	(0.31)	(0.33)
Days Payables Outstanding	6.7K	39.4K	10.4K	12.6K	12.8K	12.1K
Income Quality	1.07	0.79	0.95	0.83	0.84	0.66
Roe	(0.45)	(0.5)	(0.35)	(0.85)	(6.72)	(6.38)
Ev To Operating Cash Flow	0.29	1.16	0.35	0.81	0.0419	0.0439
Pe Ratio	(1.56)	(1.04)	(2.45)	(0.54)	(0.26)	(0.28)
Return On Tangible Assets	(0.45)	(0.47)	(0.33)	(0.74)	(2.7)	(2.84)
Ev To Free Cash Flow	0.28	1.16	0.35	0.81	0.0418	0.0439
Earnings Yield	(0.64)	(0.96)	(0.41)	(1.85)	(3.8)	(3.61)
Intangibles To Total Assets	0.25	0.1	0.0489	0.053	0.0609	0.0578
Net Debt To E B I T D A	1.69	1.99	3.0	1.17	0.3	0.28
Current Ratio	8.94	9.15	11.88	7.16	3.31	3.82
Tangible Book Value Per Share	103.32	73.28	25.02	12.24	1.83	1.93
Graham Number	486.74	281.52	74.45	57.08	22.55	21.42
Shareholders Equity Per Share	152.86	83.74	26.46	13.08	1.83	1.74
Debt To Equity	0.0171	0.0113	0.002867	0.001075	0.0159	0.0167
Graham Net Net	87.39	67.37	22.99	10.7	1.0	1.05
Interest Debt Per Share	8.04	1.01	0.0784	0.0167	0.0316	0.03
Debt To Assets	0.0129	0.009382	0.002575	8.9E-4	0.006406	0.006086
Enterprise Value Over E B I T D A	0.28	0.93	0.36	0.65	0.0347	0.0365
Short Term Coverage Ratios	(28.37)	(57.77)	(117.1)	(652.09)	(352.75)	(370.38)
Price Earnings Ratio	(1.56)	(1.04)	(2.45)	(0.54)	(0.26)	(0.28)
Price Book Value Ratio	0.7	0.52	0.86	0.46	1.77	1.86
Price Earnings To Growth Ratio	0.0167	0.0267	0.0315	(0.0287)	(0.0233)	(0.0221)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

When determining whether Hepion Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hepion Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hepion Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hepion Pharmaceuticals Stock:

How To Invest In Hepion

Details

Is Hepion Stock a good investment?

Details

What is Hepion Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.40)

Return On Assets

(0.93)

Return On Equity

(1.90)

The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Hepion Historical Financial Ratios

About Hepion Financial Ratios Analysis

Hepion Pharmaceuticals Financial Ratios Chart

Average Payables

Payables Turnover

Hepion Pharmaceuticals fundamentals Correlations

Hepion Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Hepion Pharmaceuticals fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY